Search research articles
Contact Us
Filters
Showing results (11-20 of 194) with videos related to
Page
of 20
Sort By:
Expert Review of Anti-Infective Therapy
|
October 4, 2012
Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies
Esteban C Nannini, G Ralph Corey, Martin E Stryjewski
Expert Opinion on Pharmacotherapy
|
November 15, 2011
Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia
Ethan Rubinstein, G Ralph Corey, Martin E Stryjewski, et al.
Nature Reviews. Drug Discovery
|
December 2, 2009
Telavancin
G Ralph Corey, Martin E Stryjewski, Wim Weyenberg, et al.
Antimicrobial Agents and Chemotherapy
|
August 7, 2015
Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance
Richard Pushkin, Steven L Barriere, Whedy Wang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 5, 2014
Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus
G Ralph Corey, Ethan Rubinstein, Martin E Stryjewski, et al.
BMC Infectious Diseases
|
April 9, 2014
Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies
Steven L Barriere, Martin E Stryjewski, G Ralph Corey, et al.
Diagnostic Microbiology and Infectious Disease
|
January 1, 2017
Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolates
Jennifer I Smart, G Ralph Corey, Martin E Stryjewski, et al.
The Journal of Antimicrobial Chemotherapy
|
March 15, 2012
Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections
Martin E Stryjewski, Steven L Barriere, William O'Riordan, et al.
Antimicrobial Agents and Chemotherapy
|
August 8, 2012
TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections
Martin E Stryjewski, Peter D Potgieter, Yu-Ping Li, et al.
Antimicrobial Agents and Chemotherapy
|
January 15, 2014
Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival
G Ralph Corey, Marin H Kollef, Andrew F Shorr, et al.
Page
of 20
Search research articles
Search
Showing results (11-20 of 194) with videos related to
Sort By:
Page
of 20
Expert Review of Anti-Infective Therapy
|
October 4, 2012
Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies
Esteban C Nannini, G Ralph Corey, Martin E Stryjewski
Expert Opinion on Pharmacotherapy
|
November 15, 2011
Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia
Ethan Rubinstein, G Ralph Corey, Martin E Stryjewski, et al.
Nature Reviews. Drug Discovery
|
December 2, 2009
Telavancin
G Ralph Corey, Martin E Stryjewski, Wim Weyenberg, et al.
Antimicrobial Agents and Chemotherapy
|
August 7, 2015
Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance
Richard Pushkin, Steven L Barriere, Whedy Wang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 5, 2014
Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus
G Ralph Corey, Ethan Rubinstein, Martin E Stryjewski, et al.
BMC Infectious Diseases
|
April 9, 2014
Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies
Steven L Barriere, Martin E Stryjewski, G Ralph Corey, et al.
Diagnostic Microbiology and Infectious Disease
|
January 1, 2017
Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolates
Jennifer I Smart, G Ralph Corey, Martin E Stryjewski, et al.
The Journal of Antimicrobial Chemotherapy
|
March 15, 2012
Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections
Martin E Stryjewski, Steven L Barriere, William O'Riordan, et al.
Antimicrobial Agents and Chemotherapy
|
August 8, 2012
TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections
Martin E Stryjewski, Peter D Potgieter, Yu-Ping Li, et al.
Antimicrobial Agents and Chemotherapy
|
January 15, 2014
Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival
G Ralph Corey, Marin H Kollef, Andrew F Shorr, et al.
Page
of 20